Frequency Therapeutics Strengthens Scientific Advisory Board with Addition of Leading Experts in Neurology, Stem Cell and Regenerative Medicine
Robin Franklin, Ph.D, Professor of Stem Cell Medicine at the Wellcome Trust-MRC Cambridge Stem Cell Institute
Sheng Ding, Ph.D., William K. Bowes, Jr. Distinguished Investigator and Professor at Gladstone Institute
WOBURN, Mass., August 14, 2018 – Frequency Therapeutics, a clinical stage biotechnology company, today announced the addition of two new members to its PCA Regenerative Medicine Scientific Advisory Board, Robin Franklin, Ph.D., Professor of Stem Cell Medicine at the Wellcome Trust-MRC Cambridge Stem Cell Institute, Director of the MS Society Cambridge Centre for Myelin Repair and Fellow of the Academy of Medical Sciences and Sheng Ding, Ph.D., William K. Bowes, Jr. Distinguished Investigator and Professor at Gladstone Institute of Cardiovascular Disease, and Department of Pharmaceutical Chemistry, University of California San Francisco. These two individuals bring combined decades of experience in stem cell biology and regeneration including the use of small molecules to control and activate cell functions.
“Frequency continues to bring together world-renowned scientists with extensive expertise in the fields of stem cell biology and regenerative medicine to build and guide our growing PCA Regeneration pipeline in areas such as diabetes, muscle conditions and demyelination diseases,” said Chris Loose, Ph.D., Co-founder and CSO of Frequency. “The additions of Dr. Franklin and Dr. Ding to our PCA Regenerative Medicine SAB will provide sound guidance and deep knowledge to our scientific leadership as we explore new therapeutic opportunities.”
“Frequency’s PCA approach presents a unique opportunity to address stem cell regeneration and tissue repair through the use of small molecules, something I have devoted my career to understanding,” said Dr. Ding. “I am honored to join this prestigious group of individuals on the Regenerative Medicine Advisory Board and eager to provide my knowledge and research expertise to this burgeoning company.”
PCA Regeneration, also known as Progenitor Cell Activation, utilizes small molecules locally administered to temporarily stimulate dormant cells in the body’s niche micro-environment to address biological deficits and restore healthy tissue. This is conducted without the complexity or risks of generational or systemic issues typically associated with cell and gene therapies. This novel approach has the potential to yield a whole new category of disease-modifying therapeutics for a wide range of conditions and diseases including hearing loss, demyelination diseases such as multiple sclerosis, muscle conditions, diabetes and gastrointestinal indications.
“Having spent years studying CNS regeneration with a particular focus on remyelination, the potential for PCA Regeneration to be applied to this work has strong precedent,” said Dr. Franklin. “I look forward to working with the Frequency team to provide guidance and insight on the potential use of PCA Regeneration to treat such a complicated CNS indication as demyelinating diseases and to further develop the Company’s PCA technology as a potentially safer and simpler approach to treating disease.”
Dr. Franklin and Dr. Ding join a prestigious groups of individuals on Frequency’s PCA Scientific Advisory Board which includes Sean Morrison, Ph.D., a Howard Hughes Medical Institute Investigator, Siddhartha Mukherjee, M.D., D.Phil., of Columbia University, Lee Rubin, Ph.D., of the Harvard Stem Cell Institute, Amy Wagers, Ph.D., of Harvard University and the Joslin Diabetes Center, Frequency’s CSO Chris Loose, Ph.D., and Frequency’s co-scientific founders, Bob Langer, Sc.D., of MIT and Jeff Karp, Ph.D., of Harvard Medical School and Brigham and Women’s Hospital.
The Frequency Therapeutics PCA Regenerative Medicine Scientific Advisory Board New Members:
• Robin Franklin, Ph.D., is Professor of Stem Cell Medicine. He obtained his undergraduate degrees in Physiology and Veterinary Medicine and his Ph.D. in Neuroscience. He has worked predominantly on the biology of myelin regeneration (remyelination) and investigating strategies by which this important regenerative process may be enhanced therapeutically. He is at the forefront of studying the cellular mechanisms of remyelination, providing insights into how adult stem cells are recruited to areas of demyelination and the extrinsic and intrinsic factors that regulate their differentiation into remyelinating oligodendrocytes and other glial cell types. He is also Director of the UK MS Society Cambridge Centre for Myelin Repair, a consortium of Cambridge-based scientists and clinicians working towards stem-cell-based therapies for myelin regeneration. He is a Fellow of the Academy of Medical Sciences.
• Sheng Ding, Ph.D., is William K. Bowes, Jr. Distinguished Investigator and Professor at Gladstone Institute of Cardiovascular Disease, and Department of Pharmaceutical Chemistry, University of California San Francisco. Dr. Ding earned his Ph.D. in chemistry from the Scripps Research Institute and his B.S. in chemistry from the California Institute of Technology. Dr. Ding has pioneered the development and application of innovative chemical approaches to stem cell biology and regeneration, with a focus on discovering and characterizing novel small molecules that can control various cell fate/function, including stem cell maintenance, activation, differentiation and reprogramming.
ABOUT PCA REGENERATION
Tissue regeneration with Progenitor Cell Activation, or PCA Regeneration, is a new therapeutic approach to repairing damaged tissue and restoring health function in a less complex and potentially safer manner than traditional cell and gene therapy. The approach, based on discoveries in progenitor cell biology from the labs of Bob Langer, Sc.D., at MIT and Jeff Karp, Ph.D., at Harvard Medical School and Brigham and Women’s Hospital, utilizes small molecules to awaken dormant progenitor cells already in the body and has the opportunity to address numerous degenerative diseases such as hearing loss, demyelinating diseases, skin disorders and gastrointestinal conditions.
ABOUT FREQUENCY THERAPEUTICS
Frequency Therapeutics develops small molecule drugs to stimulate cells in the body to reverse biological deficits and restore healthy tissue. Through the transitory activation of these cells, Frequency enables disease modification without the complexity of genetic engineering. Our ground-breaking therapy uses a proprietary combination of small-molecule drugs that induce progenitor cells to multiply and create new cells. While Frequency’s lead program targets hearing restoration, our PCA Regeneration platform has the potential to touch upon a wide breadth of disease indications. www.frequencytx.com.
# # #
Stefanie Tuck or Kari Watson
MacDougall Biomedical Communications